Articles from Shah Capital
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting
Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi
By Shah Capital · Via GlobeNewswire · May 20, 2024
Shah Capital Launches Campaign Urging Stockholders to Vote AGAINST the Re-Election of All of Novavax’s Directors Up for Election at its 2024 Annual Meeting
Highlights Novavax’s Massive Untapped Value That it Believes is Being Hindered by an Overly Conservative Board and Management That Clings to Failed Strategies and Have Undermined Stockholder Value
By Shah Capital · Via GlobeNewswire · May 6, 2024
Shah Capital nominates two highly qualified independent director candidates for Novavax
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price
By Shah Capital · Via GlobeNewswire · April 15, 2024